Sanofi's Oral Aubagio Jostles For Position In Multiple Sclerosis Market
This article was originally published in The Pink Sheet Daily
FDA accepts filing for teriflunomide, but concerns about pregnancy risk in a young patient population and questions about comparative efficacy could limit market potential.
You may also be interested in...
Wall Street projects modest sales for Sanofi/Genzyme’s recently approved MS drug, but by pricing it well below Gilenya and somewhat below established, widely used injectable drugs, the companies may position Aubagio for first-line use and greater than anticipated adoption by payers.
FDA approved Aubagio for patients with relapsing forms of multiple sclerosis on Sept. 12. Sponsor Genzyme, owned by Sanofi, announced an annual price of $45,000 for the drug, below the only other oral therapy for MS, Novartis’ Gilenya.
Genzyme, a Sanofi company, set the bar high for its multiple sclerosis contender by stacking it up against Roche’s interferon beta-1a in Phase III trials and got the results it was looking for, with a filing set for this quarter.